In this article, we will be taking a look at the 5 Best Up and Coming Pharmaceutical Stocks to Buy Now. If you wish to see the full list, visit 8 Best Up and Coming Pharmaceutical Stocks to Buy Now.
5. LB Pharmaceuticals Inc. (NASDAQ:LBRX)
Number of Hedge Fund Holders: 24
LB Pharmaceuticals Inc. (NASDAQ:LBRX) is one of the best up and coming stocks on our list.
TheFly reported on May 28 that Clear Street maintained a Buy rating and a $45 price target for LBRX. The firm stated that Neumora Therapeutics’ Phase 3 KOASTAL trial setback does not materially impact the outlook for LB-102. Clear Street highlighted that LB-102 is supported by established dopamine D2/D3 and serotonin 5-HT7 receptor activity, along with prior clinical evidence from related therapies. The firm also noted that LB-102 has shown strong Phase 2 results in schizophrenia and believes the company’s broader opportunities across schizophrenia, bipolar disorder, and major depressive disorder remain unchanged.
In addition to that, earlier on May 12, in its latest reported earnings for fiscal Q1 2026, LB Pharmaceuticals Inc. (NASDAQ:LBRX) provided a corporate update and reported financial results for the quarter ended March 31, 2026. Research and development expenses increased to $14.6 million, driven by higher clinical trial activity, manufacturing costs for LB-102, preclinical programs, and expanded personnel expenses. General and administrative expenses rose to $7.5 million due to increased staffing, stock-based compensation, and professional fees. The company reported a net loss of $19.1 million for the quarter. LB Pharmaceuticals ended the period with approximately $365.6 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q2 2029.
LB Pharmaceuticals Inc. (NASDAQ:LBRX) is a late-stage biotech company developing neuropsychiatric therapies, including LB-102, a novel treatment candidate for schizophrenia, bipolar depression, and major depressive disorder.
4. Lexeo Therapeutics, Inc. (NASDAQ:LXEO)
Number of Hedge Fund Holders: 26
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is one of the best up and coming stocks on our list.
TheFly reported on June 25 that JPMorgan adjusted its price target for LXEO, lowering it to $9 from $12 while maintaining an Overweight rating on the shares. The firm stated that the revision was based on an updated valuation model incorporating the company’s latest developments and recent updates.
Separately, on June 15, Lexeo Therapeutics, Inc. (NASDAQ:LXEO) announced the completion of the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan for LX2006, its gene therapy candidate targeting Friedreich’s ataxia cardiomyopathy. The finalized study design is intended to support a potential FDA biologics license application submission under the accelerated approval pathway in 2028. The FDA confirmed that no additional nonclinical bridging studies are required, allowing LXEO to proceed with patient dosing using its optimized manufacturing process. The company expects SUNRISE-FA 2 topline data in the second half of 2027, followed by a potential BLA submission in the first half of 2028.
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a clinical-stage biotech company developing AAV-based gene therapies for genetic cardiovascular diseases and APOE4-associated Alzheimer’s disease.
3. Alto Neuroscience, Inc. (NYSE:ANRO)
Number of Hedge Fund Holders: 30
Alto Neuroscience, Inc. (NYSE:ANRO) is one of the best up and coming stocks on our list.
On June 15, ALTO highlighted the publication in Nature Medicine of Prime-Praxol, an independent randomized, double-blind, placebo-controlled study evaluating pramipexole, a dopamine agonist, in patients with mood disorders and clinically significant anhedonia. The trial, independently conducted and funded by investigators at Lund University in Sweden, included adults with major depressive disorder, dysthymia, or bipolar depression. Participants received flexible-dose pramipexole or placebo alongside existing treatment for nine weeks, followed by a six-month open-label extension. The study showed that pramipexole produced a greater reduction in anhedonia compared with placebo, with improvements sustained during the extension period.
In another company news, it was reported on May 28 that Alto Neuroscience, Inc. (NYSE:ANRO) announced the appointment of Andrew Miller, Ph.D., to its Board of Directors, effective May 27, 2026. The company highlighted Dr. Miller’s extensive experience in neuropsychiatric drug development, strategic leadership, and advancing novel therapies for serious mental health conditions. Miller previously served as Founder and President of R&D at Karuna Therapeutics, where he played a key role in developing KarXT, a schizophrenia treatment later acquired by Bristol Myers Squibb. ALTO noted that its expertise will support the company as it advances ALTO-207 in treatment-resistant depression and progresses its broader precision psychiatry pipeline toward future clinical milestones.
Alto Neuroscience, Inc. (NYSE:ANRO) is a clinical-stage biotech company developing personalized treatments for neuropsychiatric disorders using its AI-driven Precision Psychiatry Platform.
2. Septerna, Inc. (NASDAQ:SEPN)
Number of Hedge Fund Holders: 31
Septerna, Inc. (NASDAQ:SEPN) is one of the best up and coming stocks on our list.
TheFly reported on June 11 that Guggenheim began coverage of SEPN with a Buy rating and assigned the company a $52 price target.
In another operational update, Septerna, Inc. (NASDAQ:SEPN) highlighted progress with SEP-479, announcing on June 8 that the first comprehensive preclinical characterization of the candidate had been accepted for an oral presentation at the 2026 Endocrine Society’s Annual Meeting (ENDO 2026). The presentation will focus on the pharmacological profile of SEP-479, a selective small-molecule PTH1R agonist being developed as a potential oral treatment for hypoparathyroidism. SEPN reported that preclinical studies demonstrated strong activity in both laboratory and animal models, supporting the candidate’s potential as an oral therapy.
SEP-479 is currently being evaluated in a Phase 1 trial involving healthy volunteers, with initial data expected in late 2026 or early 2027. The company stated that these findings further demonstrate the potential of its Native Complex Platform to develop oral small molecules targeting challenging GPCR pathways. SEPN believes SEP-479 could provide a once-daily oral approach designed to replace PTH activity and potentially improve treatment options for patients with hypoparathyroidism.
Septerna, Inc. (NASDAQ:SEPN) is a clinical-stage biotech company developing oral small-molecule drugs targeting GPCRs to treat endocrine, immune, inflammatory, and metabolic diseases.
1. Mineralys Therapeutics, Inc. (NASDAQ:MLYS)
Number of Hedge Fund Holders: 53
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is one of the best up and coming stocks on our list.
TheFly reported on June 14 that MLYS presented new data evaluating the impact of lorundrostat on heart failure risk biomarkers. The post hoc analysis examined circulating protein biomarker data from participants in the Launch-HTN and Advance-HTN clinical trials and was presented during a late-breaking poster session at ENDO 2026. The analysis showed that lorundrostat influenced key components of the renin-angiotensin-aldosterone system, including increased renin levels and reduced angiotensinogen. Treatment was also associated with declines in several biomarkers linked to heart failure risk, including NT-proBNP. The findings supported further investigation of lorundrostat’s potential role in addressing biological pathways involved in heart failure.
Moreover, to support its future growth initiatives and strengthen its financial position, Mineralys Therapeutics, Inc. (NASDAQ:MLYS) announced the pricing of an underwritten public offering of 5.66 million shares of common stock at $26.50 per share on June 3. The offering is expected to generate approximately $150 million in gross proceeds before fees and expenses. MLYS plans to use the net proceeds to help fund a portion of the $200 million upfront payment related to the repurchase of its royalty obligation under its license agreement with Tanabe Pharma Corporation. The offering followed the company’s announcement of a $500 million committed debt facility managed by Pharmakon Advisors.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) is a clinical-stage biotech company developing therapies for aldosterone-driven diseases, including resistant hypertension and chronic kidney disease.
While we acknowledge the potential of MLYS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MLYS and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 UK Stocks with the Highest Dividends and 10 Best Falling Stocks to Invest In According to Analysts.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
